Stock Screener App

Gratuito -

Installare

Drug Manufacturers - General

58.31

0.60% 0.43

Bristol Myers Squibb Co (BMY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BMY Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

John G Ullman & Associates Inc. Decreases Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Is Bristol Myers Squibb Stock a Buy? - The Motley Fool

Primecap Management Co. CA Has $1.21 Billion Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Commerce Bank Sells 30,241 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

77,494 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by B. Metzler seel. Sohn & Co. Holding AG - MarketBeat

Vital Signs: Merck maps Keytruda's next act in the injectables marketplace - FirstWord Pharma

Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Premier Fund Managers Ltd Takes Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

CAMZYOS™ Honoured with the Prix Galien Canada Innovative Product Award - cnhinews.com

GLP-1 Analogues Market Outlook: Rapid Growth at 21.3% CAGR to Surpass USD 322.85 Billion by 2034 | PMR - GlobeNewswire Inc.

BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD - Barchart

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu - Fierce Biotech

Bristol-Myers Squibb (NYSE:BMY) Shares Sold by PNC Financial Services Group Inc. - MarketBeat

BMS CFO backs “resilient” pharma industry amid RFK’s impending governance - Pharmaceutical Technology

OneAscent Financial Services LLC Purchases Shares of 8,855 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY) - Nasdaq

Bristol Myers to Present 90+ Studies at ASH, Including 5-Year Breyanzi Data | BMY Stock News - StockTitan

Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Natixis Advisors LLC - MarketBeat

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - Benzinga

Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now? - Insider Monkey

EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer - Pharmaceutical Technology

Bristol-Myers Squibb: Buy This Bargain Stock Before It's Gone (NYSE:BMY) - Seeking Alpha

Swiss National Bank Boosts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Kinsale Capital Group Inc. Purchases 18,163 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Mizuho Markets Americas LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Kentucky Retirement Systems Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch

Bristol-Myers Squibb (NYSE:BMY) Trading Down 3%Here's Why - MarketBeat

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - BioSpace

Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue - Benzinga

EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims - FiercePharma

Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sheaff Brock Investment Advisors LLC - MarketBeat

BMYBristol-Myers Squibb Co. Latest Stock News & Market Updates - StockTitan

Cornercap Investment Counsel Inc. Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Bristol-Myers Squibb (NYSE:BMY) Now Covered by Analysts at Wolfe Research - MarketBeat

Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace

Bristol Myers' Cancer Drug Repotrectinib Gains Key EU Panel Backing for Lung Cancer | BMY Stock News - StockTitan

The Bristol Myers Squibb Foundation - Bristol Myers Squibb

Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug - MSN

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug - Reuters

Justice on the Move: The Impact of Bristol-Myers Squibb on FLSA Forum-Shopping - The National Law Review

9,269 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by Sargent Investment Group LLC - MarketBeat

Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week - Yahoo Finance

Bristol-Myers Squibb (NYSE:BMY) Stake Lessened by KBC Group NV - MarketBeat

Plato Investment Management Ltd Purchases 13,447 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Clinical trials & studies - Bristol Myers Squibb

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024 - Indian Pharma Post

ICICI Prudential Asset Management Co Ltd Sells 38,500 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now? - Insider Monkey

Oppenheimer & Co. Inc. Raises Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink - FiercePharma

Pinnacle Financial Partners Inc Acquires 272,439 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Mengis Capital Management Inc. Has $3.37 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Aigen Investment Management LP Sells 102,823 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Equities Analysts Issue Forecasts for BMY Q4 Earnings - MarketBeat

Bristol-Myers Squibb (NYSE:BMY) Upgraded by Leerink Partnrs to "Strong-Buy" Rating - MarketBeat

Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch

Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $60.00 at Citigroup - MarketBeat

This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga

Bristol-Myers Squibb's $14 Billion PotentialAnalyst Upgrades Stock - Benzinga

BMO Capital Markets Boosts Bristol-Myers Squibb (NYSE:BMY) Price Target to $61.00 - MarketBeat

AbbVie’s loss is Bristol Myers Squibb’s gainanalyst - Proactive Investors USA

American Assets Inc. Purchases New Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

SNY

$47.95

0.37%

PFE

$24.95

0.04%

AMGN

$290.00

0.60%

NVS

$103.85

0.72%

MRK

$99.47

2.05%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters